Viral therapy for pancreatic cancer: Tackle the bad guys with poison

Cancer Letters

Volumn 333, Issue 1, 2013, Pages 1-8

  Xu, Can ^a   Li, Haihang ^a   Su, Changqing ^b   Li, Zhaoshen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adenovirus; Herpes simplex virus; Oncolytic virus therapy; Pancreatic cancer

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CANCER VACCINE; FUSON H2; G 207; GAMMA INTERFERON; GEMCITABINE; HEAT SHOCK PROTEIN 70; LONTUCIREV; MODIFIED VACCINIA VIRUS ANKARA SURVIVIN VACCINE; MOLECULAR THERAPY AGENT; NV 1020; NV 1023; NV 1060; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS 6 MICRORNA 122; ONCOLYTIC ADENOVIRUS DELTA DELTA; ONCOLYTIC HERPES VIRUS; ONCOLYTIC HERPES VIRUS HF10; ONCOLYTIC HERPES VIRUS HRR3; ONCOLYTIC HERPES VIRUS R3616; ONCOLYTIC MEASLE VIRUS; ONCOLYTIC PARVOVIRUS; ONCOLYTIC PARVOVIRUS H 1; ONCOLYTIC REOVIRUS; ONCOLYTIC VIRUS; ONCORINE; TALIMOGENE LAHERPAREPVEC; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIROTHERAPY AGENT;

ADENOVIRUS; ADENOVIRUS 5; ADENOVIRUS 6; CASTRATION RESISTANT PROSTATE CANCER; DNA MODIFICATION; DRUG EFFICACY; DRUG RESPONSE; GENE DELETION; HEAD AND NECK CANCER; HUMAN; LIVER TOXICITY; METASTASIS; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; RNA INTERFERENCE; SHORT SURVEY; SOLID TUMOR; TREATMENT OUTCOME; VIRAL GENE THERAPY; VIROTHERAPY;

ADENOVIRIDAE; SIMPLEXVIRUS;

EID: 84876081415     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.035     Document Type: Review

References (91)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2009, 59(2009):225-249.
2. Campen C.J., Dragovich T., Baker A.F. Management strategies in pancreatic cancer. Am. J. Health Syst. Pharm. 2011, 68:573-584.
3. Nentwich M.F., Bockhorn M., Konig A., Izbicki J.R., Cataldegirmen G. Surgery for advanced and metastatic pancreatic cancer-current state and trends. Anticancer Res. 2012, 32:1999-2002.
4. Morganti A.G., Massaccesi M., La Torre G., Caravatta L., Piscopo A., Tambaro R., Sofo L., Sallustio G., Ingrosso M., Macchia G., Deodato F., Picardi V., Ippolito E., Cellini N., Valentini V. A systematic review of resectability and survival after concurrent chemoradiation in primarily unrespectable pancreatic cancer. Ann. Surg. Oncol. 2010, 17:194-205.
5. Gillen S., Schuster T., Friess H., Kleeff J. Palliative resections versus palliative bypass procedures in pancreatic cancer - a systematic review. Am. J. Surg. 2012, 203:496-502.
6. Riediger H., Keck T., Wellner U., zurHausen A., Adam U., Hopt U.T., Makowiec F. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J. Gastrointest. Surg. 2009, 13:1337-1344.
7. Matsuoka L., Selby R., Genyk Y. The surgical management of pancreatic cancer. Gastroenterol. Clin. North Am. 2012, 41:211-221.
8. Heinemann V., Haas M., Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat. Rev. 2012, 38:843-853.
9. Abrams R.A. Radiotherapy in the adjuvant management of pancreatic adenocarcinoma: is it helpful?. Expert Rev. Gastroenterol. Hepatol. 2012, 6:149-161.
10. Calvo F.A., Valentini V. Radiotherapy for pancreatic cancer: systematic nihilism or intraoperative realism. Radiother. Oncol. 2008, 87:314-317.
11. Wilkowski R., Wolf M., Heinemann V. Primary advanced unrespectable pancreatic cancer. Recent Results Cancer Res. 2008, 177:79-93.
12. Ruano-Ravina A., Almazan Ortega R., Guedea F. Intraoperative radiotherapy in pancreatic cancer: a systematic review. Radiother. Oncol. 2008, 87:318-325.
13. Zygogianni G.A., Kyrgias G., Kouvaris J., Antypas C., Skarlatos J., Armpilia C., Nikiteas N., Kouloulias E.V. Intraoperative radiation therapy on pancreatic cancer patients: a review of the literature. Minerva Chir. 2011, 66:361-369.
14. Kimple R.J., Russo S., Monjazeb A., Blackstock A.W. The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. Expert Rev. Anticancer Ther. 2012, 12:469-480.
15. Lott J.B. Oncolytic viruses: a new paradigm for treatment of head and neck cancer. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2012, 113:155-160.
16. Sivendran S., Pan M., Kaufman H.L., Saenger Y. Herpes simplex virus oncolytic vaccine therapy in melanoma. Expert Opin. Biol. Ther. 2010, 10:1145-1153.
17. Guse K., Cerullo V., Hemminki A. Oncolytic vaccinia virus for the treatment of cancer. Expert Opin. Biol. Ther. 2011, 11:595-608.
18. Eager R.M., Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther. 2011, 18:305-317.
19. Thirukkumaran C., Morris D.G. Oncolytic viral therapy using reovirus. Methods Mol. Biol. 2009, 542:607-634.
20. Cerullo V., Koski A., Vaha-Koskela M., Hemminki A. Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. Adv. Cancer Res. 2012, 115:265-318.
21. Heise C.C., Williams A.M., Xue S., Propst M., Kirn D.H. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 1999, 59:2623-2628.
22. Hecht J.R., Bedford R., Abbruzzese J.L., Lahoti S., Reid T.R., Soetikno R.M., Kirn D.H., Freeman S.M. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unrespectable pancreatic carcinoma. Clin. Cancer Res. 2003, 9:555-561.
23. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. 2006, 98:298-300.
24. Yu W., Fang H. Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets 2007, 7:141-148.
25. Oberg D., Yanover E., Adam V., Sweeney K., Costas C., Lemoine N.R., Hallden G. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin. Cancer Res. 2010, 16:541-553.
26. Cherubini G., Kallin C., Mozetic A., Hammaren-Busch K., Muller H., Lemoine N.R., Hallden G. The oncolytic adenovirus AdDeltaDelta enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models. Gene Ther. 2011, 18:1157-1165.
27. Hallden G., Portella G. Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets. Expert Opin. Ther. Targets 2012.
28. Xu C., Sun Y., Wang Y., Yan Y., Shi Z., Chen L., Lin H., Lu S., Zhu M., Su C., Li Z. CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer. Cancer Lett. 2012, 319:154-163.
29. Chu Q.D., Sun G., Pope M., Luraguiz N., Curiel D.T., Kim R., Li B.D., Mathis J.M. Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model. Surgery 2012, 152:441-448.
30. Armstrong L., Davydova J., Brown E., Han J., Yamamoto M., Vickers S.M. Delivery of interferon alpha using a novel Cox2-controlled adenovirus for pancreatic cancer therapy. Surgery 2012, 152:114-122.
31. Armstrong L., Arrington A., Han J., Gavrikova T., Brown E., Yamamoto M., Vickers S.M., Davydova J. Generation of a novel cyclooxygenase-2-targeted interferon-expressing conditionally replicative adenovirus for pancreatic cancer therapy. Am. J. Surg. 2012.
32. Choi J.W., Lee J.S., Kim S.W., Yun C.O. Evolution of oncolytic adenovirus for cancer treatment. Adv. Drug Deliv. Rev. 2012, 64:720-729.
33. Zhang Y.A., Nemunaitis J., Samuel S.K., Chen P., Shen Y., Tong A.W. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res. 2006, 66:9736-9743.
34. Zhang Z., Zhang X., Newman K., Liu X. MicroRNA regulation of oncolytic adenovirus 6 for selective treatment of castration-resistant prostate cancer. Mol. Cancer Ther. 2012.
35. Martuza R.L., Malick A., Markert J.M., Ruffner K.L., Coen D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991, 252:854-856.
36. Li J., Zeng W., Huang Y., Zhang Q., Hu P., Rabkin S.D., Liu R. Treatment of breast cancer stem cells with oncolytic herpes simplex virus. Cancer Gene Ther. 2012, 19:707-714.
37. Tsuji T., Nakamori M., Iwahashi M., Nakamura M., Ojima T., Iida T., Katsuda M., Hayata K., Ino Y., Todo T., Yamaue H. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer. Int. J. Cancer 2012.
38. Castelo-Branco P., Passer B.J., Buhrman J.S., Antoszczyk S., Marinelli M., Zaupa C., Rabkin S.D., Martuza R.L. Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer. Gene Ther. 2010, 17:805-810.
39. Cheema T.A., Kanai R., Kim G.W., Wakimoto H., Passer B., Rabkin S.D., Martuza R.L. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin. Cancer Res. 2011, 17:7383-7393.
40. Eisenberg D.P., Carpenter S.G., Adusumilli P.S., Chan M.K., Hendershott K.J., Yu Z., Fong Y. Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway. Surgery 2010, 148:325-334.
41. Hu J.C., Coffin R.S., Davis C.J., Graham N.J., Groves N., Guest P.J., Harrington K.J., James N.D., Love C.A., McNeish I., Medley L.C., Michael A., Nutting C.M., Pandha H.S., Shorrock C.A., Simpson J., Steiner J., Steven N.M., Wright D., Coombes R.C. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 2006, 12:6737-6747.
42. Harrington K.J., Hingorani M., Tanay M.A., Hickey J., Bhide S.A., Clarke P.M., Renouf L.C., Thway K., Sibtain A., McNeish I.A., Newbold K.L., Goldsweig H., Coffin R., Nutting C.M. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin. Cancer Res. 2010, 16:4005-4015.
43. Liu B.L., Robinson M., Han Z.Q., Branston R.H., English C., Reay P., McGrath Y., Thomas S.K., Thornton M., Bullock P., Love C.A., Coffin R.S. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003, 10:292-303.
44. Varghese S., Rabkin S.D., Nielsen G.P., MacGarvey U., Liu R., Martuza R.L. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res. 2007, 67:9371-9379.
45. Smith K.D., Mezhir J.J., Bickenbach K., Veerapong J., Charron J., Posner M.C., Roizman B., Weichselbaum R.R. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J. Virol. 2006, 80:1110-1120.
46. Smith K.D., Shao M.Y., Posner M.C., Weichselbaum R.R. Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application. Future Oncol. 2007, 3:545-556.
47. Mundschau L.J., Faller D.V. Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells. Biochimie 1994, 76:792-800.
48. Sarinella F., Calistri A., Sette P., Palu G., Parolin C. Oncolysis of pancreatic tumour cells by a gamma34.5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway. Gene Ther. 2006, 13:1080-1087.
49. Kasuya H., Nishiyama Y., Nomoto S., Hosono J., Takeda S., Nakao A. Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer. J. Surg. Oncol. 1999, 72:136-141.
50. Coukos G., Makrigiannakis A., Kang E.H., Rubin S.C., Albelda S.M., Molnar-Kimber K.L. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin. Cancer Res. 2000, 6:3342-3353.
51. Watanabe I., Kasuya H., Nomura N., Shikano T., Shirota T., Kanazumi N., Takeda S., Nomoto S., Sugimoto H., Nakao A. Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Cancer Chemother. Pharmacol. 2008, 61:875-882.
52. Kasuya H., Nishiyama Y., Nomoto S., Goshima F., Takeda S., Watanabe I., Nomura N., Shikano T., Fujii T., Kanazumi N., Nakao A. Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy. Cancer Gene Ther. 2007, 14:533-542.
53. Varghese S., Rabkin S.D. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 2002, 9:967-978.
54. Mineta T., Rabkin S.D., Yazaki T., Hunter W.D., Martuza R.L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1995, 1:938-943.
55. Kim S.H., Wong R.J., Kooby D.A., Carew J.F., Adusumilli P.S., Patel S.G., Shah J.P., Fong Y. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck. Eur. J. Cancer 2005, 41:313-322.
56. Kanai R., Tomita H., Shinoda A., Takahashi M., Goldman S., Okano H., Kawase T., Yazaki T. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence. Gene Ther. 2006, 13:106-116.
57. McAuliffe P.F., Jarnagin W.R., Johnson P., Delman K.A., Federoff H., Fong Y. Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J. Gastrointest. Surg. 2000, 4:580-588.
58. Gil Z., Rein A., Brader P., Li S., Shah J.P., Fong Y., Wong R.J. Nerve-sparing therapy with oncolytic herpes virus for cancers with neural invasion. Clin. Cancer Res. 2007, 13:6479-6485.
59. Dai M.H., Zamarin D., Gao S.P., Chou T.C., Gonzalez L., Lin S.F., Fong Y. Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. Br. J. Surg. 2010, 97:1385-1394.
60. Fu X., Tao L., Li M., Fisher W.E., Zhang X. Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Clin. Cancer Res. 2006, 12:3152-3157.
61. Lowenstein P.R., Kroeger K., Castro M.G. Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses. Neurotherapeutics 2007, 4:715-724.
62. Melcher A., Parato K., Rooney C.M., Bell J.C. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol. Ther. 2011, 19:1008-1016.
63. Campadelli-Fiume G., De Giovanni C., Gatta V., Nanni P., Lollini P.L., Menotti L. Rethinking herpes simplex virus: the way to oncolytic agents. Rev. Med. Virol. 2011, 21:213-226.
64. Kaufman H.L., Kim D.W., DeRaffele G., Mitcham J., Coffin R.S., Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 2010, 17:718-730.
65. Kaufman H.L., Bines S.D. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unrespectable stage III or IV melanoma. Future Oncol. 2010, 6:941-949.
66. Kaur B., Cripe T.P., Chiocca E.A. "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr. Gene Ther. 2009, 9:341-355.
67. Simpson G.R., Han Z., Liu B., Wang Y., Campbell G., Coffin R.S. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res. 2006, 66:4835-4842.
68. Nawa A., Luo C., Zhang L., Ushjima Y., Ishida D., Kamakura M., Fujimoto Y., Goshima F., Kikkawa F., Nishiyama Y. Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy. Curr. Gene Ther. 2008, 8:208-221.
69. Nakao A., Kasuya H., Sahin T.T., Nomura N., Kanzaki A., Misawa M., Shirota T., Yamada S., Fujii T., Sugimoto H., Shikano T., Nomoto S., Takeda S., Kodera Y., Nishiyama Y. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Ther. 2011, 18:167-175.
70. Maitra R., Ghalib M.H., Goel S. Reovirus: a targeted therapeutic - progress and potential. Mol. Cancer Res. 2012.
71. Himeno Y., Etoh T., Matsumoto T., Ohta M., Nishizono A., Kitano S. Efficacy of oncolytic reovirus against liver metastasis from pancreatic cancer in immunocompetent models. Int. J. Oncol. 2005, 27:901-906.
72. Hirano S., Etoh T., Okunaga R., Shibata K., Ohta M., Nishizono A., Kitano S. Reovirus inhibits the peritoneal dissemination of pancreatic cancer cells in an immunocompetent animal model. Oncol. Rep. 2009, 21:1381-1384.
73. Galanis E., Markovic S.N., Suman V.J., Nuovo G.J., Vile R.G., Kottke T.J., Nevala W.K., Thompson M.A., Lewis J.E., Rumilla K.M., Roulstone V., Harrington K., Linette G.P., Maples W.J., Coffey M., Zwiebel J., Kendra K. Phase II trial of intravenous administration of Reolysin((R)) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol. Ther. 2012, 20:1998-2003.
74. Morris D.G., Feng X., Difrancesco L.M., Fonseca K., Forsyth P.A., Paterson A.H., Coffey M.C., Thompson B. REO-001: a phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin(R)) in patients with advanced solid tumors. Invest. New Drugs 2012, 9.
75. Grekova S., Aprahamian M., Giese N., Schmitt S., Giese T., Falk C.S., Daeffler L., Cziepluch C., Rommelaere J., Raykov Z. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent. Cancer Biol. Ther. 2011, 10:1280-1289.
76. Loktev V.B., Ivan'kina T., Netesov S.V., Chumakov P.M. Oncolytic parvoviruses. A new approaches for cancer therapy. Vestn. Ross. Akad. Med. Nauk 2012, 42-47.
77. Angelova A.L., Aprahamian M., Grekova S.P., Hajri A., Leuchs B., Giese N.A., Dinsart C., Herrmann A., Balboni G., Rommelaere J., Raykov Z. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin. Cancer Res. 2009, 15:511-519.
78. Grekova S.P., Aprahamian M., Daeffler L., Leuchs B., Angelova A., Giese T., Galabov A., Heller A., Giese N.A., Rommelaere J., Raykov Z. Interferon gamma improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer. Cancer Biol. Ther. 2011, 12:888-895.
79. Bhat R., Dempe S., Dinsart C., Rommelaere J. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int. J. Cancer 2011, 128:908-919.
80. Dempe S., Lavie M., Struyf S., Bhat R., Verbeke H., Paschek S., Berghmans N., Geibig R., Rommelaere J., Van Damme J., Dinsart C. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment. Cancer Immunol. Immunother. 2012.
81. Carlson S.K., Classic K.L., Hadac E.M., Dingli D., Bender C.E., Kemp B.J., Russell S.J. Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. AJR Am. J. Roentgenol. 2009, 192:279-287.
82. Penheiter A.R., Wegman T.R., Classic K.L., Dingli D., Bender C.E., Russell S.J., Carlson S.K. Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. AJR Am. J. Roentgenol. 2010, 195:341-349.
83. Bossow S., Grossardt C., Temme A., Leber M.F., Sawall S., Rieber E.P., Cattaneo R., von Kalle C., Ungerechts G. Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Ther. 2011, 18:598-608.
84. Tysome J.R., Briat A., Alusi G., Cao F., Gao D., Yu J., Wang P., Yang S., Dong Z., Wang S., Deng L., Francis J., Timiryasova T., Fodor I., Lemoine N.R., Wang Y. Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther. 2009, 16:1223-1233.
85. Ishizaki H., Manuel E.R., Song G.Y., Srivastava T., Sun S., Diamond D.J., Ellenhorn J.D. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol. Immunother. 2011, 60:99-109.
86. Yu Y.A., Galanis C., Woo Y., Chen N., Zhang Q., Fong Y., Szalay A.A. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol. Cancer Ther. 2009, 8:141-151.
87. Hiley C.T., Yuan M., Lemoine N.R., Wang Y. Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours. Gene Ther. 2010, 17:281-287.
88. Hance K.W., Rogers C.J., Zaharoff D.A., Canter D., Schlom J., Greiner J.W. The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines. Clin. Cancer Res. 2009, 15:2387-2396.
89. Kaufman H.L., Kim-Schulze S., Manson K., DeRaffele G., Mitcham J., Seo K.S., Kim D.W., Marshall J. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J. Transl. Med. 2007, 5:60.
90. Wennier S.T., Liu J., Li S., Rahman M.M., Mona M., McFadden G. Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer. Mol. Ther. 2012, 20:759-768.
91. Woo Y., Kelly K.J., Stanford M.M., Galanis C., Chun Y.S., Fong Y., McFadden G. Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Ann. Surg. Oncol. 2008, 15:2329-2335.